<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00345982</url>
  </required_header>
  <id_info>
    <org_study_id>2005/150</org_study_id>
    <nct_id>NCT00345982</nct_id>
  </id_info>
  <brief_title>Augmenting Clozapine With Sertindole - SERCLOZ</brief_title>
  <official_title>Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether addition of sertindole to clozapine
      treatment can improve psychosis or the metabolic side-effects of clozapine in patients with
      treatment-resistant schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Around 20 % of patients with schizophrenia are treatment-resistant. Clozapine is still the
      drug of choice for these patients but 2/3 will not respond adequately to clozapine. In the
      study clozapine treatment is augmented with sertindole. Patients are randomized to either
      clozapine or sertindole for 12 weeks and continue in a open-label study with sertindole for
      12 weeks. The purpose of the open-label study is to determine whether clozapine dosage can be
      reduced due to the addition of sertindole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS total score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GAF</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHOQOL-BREF</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAI</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive test</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb1Ac</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertindole 16 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serdolect</intervention_name>
    <description>16 mg, 12 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>sertindole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICD10 diagnosis of schizophrenia (F20.0-3)

          -  Clozapine treatment minimum 6 months

          -  Total PANSS &gt;65

          -  No antipsychotic other than clozapine drug 1 month prior inclusion

        Exclusion Criteria:

          -  QTc &gt;500 ms

          -  Violence to SPC of clozapine or Serdolect

          -  Major depression

          -  Significant substance misuse interfering with participating in the study

          -  Cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmi Nielsen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg Psychiatric Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Psychiatric Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2006</study_first_posted>
  <last_update_submitted>September 24, 2010</last_update_submitted>
  <last_update_submitted_qc>September 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jimmi Nielsen, M.D</name_title>
    <organization>Aalborg Psychiatric Hospital</organization>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Treatment-resistant</keyword>
  <keyword>sertindole</keyword>
  <keyword>clozapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Sertindole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

